HURA - NASDAQ
TuHURA Biosciences, Inc.
$2.27
+9.4%TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
At a Glance
Live Snapshothura
Research Development Expenses
Last Annual Value
20.53M
3-Year CAGR
30%
5-Year CAGR
12%
10-Year CAGR
20%
TuHURA Biosciences, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
TuHURA Biosciences, Inc. NASDAQ:HURA | 20.53M | 97.6% | 6.2% | 15.2% | |
 Cognition Therapeutics, Inc. NASDAQ:CGTX | 37.19M | -0.0% | 14.9% | N/A | |
 Seer, Inc. NASDAQ:SEER | 43.87M | -2.6% | 8.5% | N/A | |
 Context Therapeutics Inc. NASDAQ:CNTX | 31.86M | 21.5% | 53.0% | N/A | |
 Ovid Therapeutics Inc. NASDAQ:OVID | 25.58M | -3.6% | -11.4% | 10.3% | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 23.72M | -11.1% | 3.5% | 15.4% | |
 Inovio Pharmaceuticals, Inc. NASDAQ:INO | 54.21M | -14.5% | -26.3% | -4.8% | |
 Agenus Inc. NASDAQ:AGEN | 79.34M | -30.3% | -15.0% | -1.8% | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 49.06M | -25.3% | -19.1% | -5.0% | |
 Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | 104.89M | 35.3% | 53.5% | N/A | |
 VistaGen Therapeutics, Inc. NASDAQ:VTGN | 39.38M | -3.9% | 27.0% | 25.9% |
TuHURA Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your HURA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.